Last week, Pfizer and BioNTech said their experimental COVID-19 vaccine was 90% effective in early interim results. And yesterday, they announced that their mRNA-based vaccine candidate is 95% effective at preventing COVID-19. Dr. Reynold Panettieri Jr. of Robert Wood Johnson Medical School, New Brunswick, New Jersey, told Medscape Medical News, “This is a game-changer. The Pfizer data hit the critical number of patients, that was 170, and showed 95% success, which was stunning data.” The clinical trial was ethnically diverse and its results were consistent across all genders and age groups, with a 94% efficacy seen in participants above 65 years of age. To read the full story.
Recent Posts
- Rutgers researchers: How Meta turned teen attention into a public health crisis.
- Kids under 5 are grabbing their parents’ vapes and getting sick at record levels, researchers say.
- These N.J. medical schools are among some of the best in the country. See how they rank.
- Estrogen Patch Shortages Are Ongoing—Here’s Where to Find Them and What to Ask Your Doctor.
- Toddlers are getting their hands on e-cigarettes and inhaling at an alarming rate, new Rutgers study shows.
Categories
- Community (2,497)
- Covid (1,001)
- CTO Events (6)
- News (3,169)
- Pilots (21)